HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic ...

Chronic kidney disease (CKD) is defined as a progressive loss of renal function that lasts for more than 3 months, and is classified according to the degree of kidney damage – measured by the le ...

Potassium is a mineral needed for vital bodily functions. But people with kidney disease may need to know which high potassium foods to avoid. Here we discuss how to create such a diet.

Tasian, a pediatric urologist at Children’s Hospital of Philadelphia who has conducted research on kidney stones in children. Tasian said the disease affects adults and children in similar ways ...

VX-407 is under clinical development by Vertex Pharmaceuticals and currently in Phase I for Polycystic Kidney Disease. According to GlobalData, Phase I drugs for Polycystic Kidney Disease have a 69% ...

"I pass this car that has a magnet on his driver's side door, and it said, 'O-negative type blood, kidney donor needed. Call this number,'" Bruens says. "And I was like, 'I, in fact, I have O ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Vertex Pharmaceuticals is trying to diversify its ... Vertex is best known for its therapies for the rare lung disease cystic fibrosis (CF). They provide the vast majority of its sales revenue ...

In this article, we are going to take a look at where Vertex Pharmaceuticals ... currently spans 5 disease verticals: sickle cell/beta thalassemia, type 1 diabetes, APOL-1 kidney disease, IgA ...

AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger’s Disease). According to GlobalData, Phase II drugs for IgA Nephropathy ...